BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 9825574)

  • 21. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
    Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
    Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
    Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
    Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
    Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
    Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
    Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
    Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
    Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
    List AF
    Leukemia; 1996 Apr; 10 Suppl 1():S36-8. PubMed ID: 8618469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
    Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
    Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
    Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
    Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
    Stone RM; Mayer RJ
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):47-64. PubMed ID: 8449864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
    Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.